The DOI matches its Crossref record; 37 of the 39 references it cites were found in a registry or an index.
VEGF-Trap: A VEGF blocker with potent antitumor effects
Open accessAbstract
Vascular endothelial growth factor (VEGF) plays a critical role during normal embryonic angiogenesis and also in the pathological angiogenesis that occurs in a number of diseases, including cancer. Initial attempts to block VEGF by using a humanized monoclonal antibody are beginning to show promise in human cancer patients, underscoring the importance of optimizing VEGF blockade. Previous studies have found that one of the most effective ways to block the VEGF-signaling pathway is to prevent VEGF from binding to its normal receptors by administering decoy-soluble receptors. The highest-affinity VEGF blocker described to date is a soluble decoy receptor created by fusing the first three Ig domains of VEGF receptor 1 to an Ig constant region; however, this fusion protein has very poor in vivo pharmacokinetic properties. By determining the requirements to maintain high affinity while extending in vivo half life, we were able to engineer a very potent high-affinity VEGF blocker that has markedly enhanced pharmacokinetic properties. This VEGF-Trap effectively suppresses tumor growth and vascularization in vivo , resulting in stunted and almost completely avascular tumors. VEGF-Trap-mediated blockade may be superior to that achieved by other agents, such as monoclonal antibodies targeted against the VEGF receptor.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The current intravitreal VEGF inhibitors in clinical use are bevacizumab (Avastin, Genentech, San Francisco, CA), ranibizumab (Lucentis, Genentech, San Francisco, CA), aflibercept (Regeneron, Tarrytown, NY), and brolucizumab (Beovu, Novartis, Basel, Switzerland) [4–8].”
From Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review (2021) · cites this paper as [6]
Citations
Cites
Angiogenesis in cancer, vascular, rheumatoid and other disease
Folkman, J. (1995) · Nature Medicine · doi:10.1038/nm0195-27 · Cited by 7,627
Vascular-specific growth factors and blood vessel formation
Yancopoulos, G. D., Davis, S., Gale, N. W., Rudge, J. S., Wiegand, S. J., & Holash, J. (2000) · Nature · doi:10.1038/35025215 · Cited by 3,699
Self-citationKim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., & Ferrara, N. (1993) · Nature · doi:10.1038/362841a0 · Cited by 3,605
Vessel Cooption, Regression, and Growth in Tumors Mediated by Angiopoietins and VEGF
Holash, J., Maisonpierre, P. C., Compton, D., Boland, P., Alexander, C. R., Zagzag, D., Yancopoulos, G. D., & Wiegand, S. J. (1999) · Science · doi:10.1126/science.284.5422.1994 · Cited by 2,195
Self-citationGerber, H.-P., Vu, T. H., Ryan, A. M., Kowalski, J., Werb, Z., & Ferrara, N. (1999) · Nature Medicine · doi:10.1038/9467 · Cited by 2,085
Adamis, A. P., Miller, J. W., Bernal, M.-T., D'Amico, D. J., Folkman, J., Yeo, T.-K., & Yeo, K.-T. (1994) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(14)75794-0 · Cited by 1,296
Fong, T. A. T., Shawver, L. K., Sun, L., Tang, C., App, H., Powell, T., Kim, Y. H., Schreck, R., Wang, X., Risau, W., et al. (1999) · PubMed · Cited by 1,109
Clinical applications of angiogenic growth factors and their inhibitors
Ferrara, N., & Alitalo, K. (1999) · Nature Medicine · doi:10.1038/70928 · Cited by 1,004
VEGF is required for growth and survival in neonatal mice
Gerber, H.-P., Hillan, K. J., Ryan, A. M., Kowalski, J., Keller, G.-A., Rangell, L., Wright, B. D., Radtke, F., Aguet, M., & Ferrara, N. (1999) · Development · doi:10.1242/dev.126.6.1149 · Cited by 915
Holash, J., Wiegand, S. J., & Yancopoulos, G. D. (1999) · Oncogene · doi:10.1038/sj.onc.1203035 · Cited by 744
Self-citation
Research works printed but not linked: 11
- Pezzella F., Pastorino, U., Tagliabue, E., Andreola, S., Sozzi, G., Gasparini, G., Menard, S., Gatter, K. C., Harris, A. L., Fox, S., et al. (1997) Am. J. Pathol.151,1417-1423.9358768
- Eriksson U. & Alitalo, K. (1999) Curr. Top. Microbiol. Immunol.237,41-57.9893345
- Ferrara N. (1999) Curr. Top. Microbiol. Immunol.237,1-30.9893343
- Prewett M., Huber, J., Li, Y., Santiago, A., O'Connor, W., King, K., Overholser, J., Hooper, A., Pytowski, B., Witte, L., Bohlen, P. & Hicklin, D. J. (1999) Cancer Res.59,5209-5218.10537299
- Millauer B., Longhi, M. P., Plate, K. H., Shawver, L. K., Risau, W., Ullrich, A. & Strawn, L. M. (1996) Cancer Res.56,1615-1620.8603410
- Fong T. A., Shawver, L. K., Sun, L., Tang, C., App, H., Powell, T. J., Kim, Y. H., Schreck, R., Wang, X., Risau, W., et al. (1999) Cancer Res.59,99-106.9892193
- Drevs J., Hofmann, I., Hugenschmidt, H., Wittig, C., Madjar, H., Muller, M., Wood, J., Martiny-Baron, G., Unger, C. & Marme, D. (2000) Cancer Res.60,4819-4824.10987292
- Wedge S. R., Ogilvie, D. J., Dukes, M., Kendrew, J., Curwen, J. O., Hennequin, L. F., Thomas, A. P., Stokes, E. S., Curry, B., Richmond, G. H., et al. (2000) Cancer Res.60,970-975.10706112
- Gerber H. P., Kowalski, J., Sherman, D., Eberhard, D. A. & Ferrara, N. (2000) Cancer Res.60,6253-6258.11103779
- Lin Y. S., Nguyen, C., Mendoza, J. L., Escandon, E., Fei, D., Meng, Y. G. & Modi, N. B. (1999) J. Pharmacol. Exp. Ther.288,371-378.9862791
- Qaum T., Xu, Q., Joussen, A. M., Clemens, M. W., Qin, W., Miyamoto, K., Hassessian, H., Wiegand, S. J., Rudge, J., Yancopoulos, G. D. & Adamis, A. P. (2001) Invest. Ophthalmol. Visual Sci.42,2408-2413.11527957
Cited by
The biology of VEGF and its receptors
Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003) · Nature Medicine · doi:10.1038/nm0603-669 · Cited by 9,591
Vascular Endothelial Growth Factor: Basic Science and Clinical Progress
Ferrara, N. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0027 · Cited by 3,687
VEGF in signaling and disease: beyond discovery and development
Apte, R. S., Chen, D. S., & Ferrara, N. (2019) · Cell · doi:10.1016/j.cell.2019.01.021 · Cited by 2,721
Angiogenesis as a therapeutic target
Ferrara, N., & Kerbel, R. S. (2005) · Nature · doi:10.1038/nature04483 · Cited by 2,653
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
Ferrara, N., Hillan, K. J., Gerber, H.-P., & Novotny, W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1381 · Cited by 2,625
“The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency.”
Background
Metadata
- Authors
- Holash, J., Davis, S., Papadopoulos, N., Croll, S. D., Ho, L., Russell, M., Boland, P., Leidich, R., Hylton, D., Burova, E., Ioffe, E., Huang, T., Radziejewski, C., Bailey, K., Fandl, J. P., Daly, T., Wiegand, S. J., Yancopoulos, G. D., & Rudge, J. S.
- Affiliations
- Regeneron (United States) (US)
- Regeneron Pharmaceuticals, Incorporated, 777 Old Saw Mill River Road, Tarrytown, NY 10591
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2002-08-12
- Volume
- 99
- Issue
- 17
- Pages
- 11393-11398
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC123267
- OpenAlex
- W1980725734
- Cited by
- 1,691
- References
- 39
- Citations by year
- 2026: 19 · 2025: 31 · 2024: 40 · 2023: 50 · 2022: 51 · 2021: 80 · 2020: 60 · 2019: 60 · 2018: 65 · 2017: 81 · 2016: 111 · 2015: 101 · 2014: 111 · 2013: 113 · 2012: 118
- FWCI
- 15.34
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Health Sciences › Medicine › Oncology › Lymphatic System and Diseases
- Keywords
- VEGF trap, vascular endothelial growth factor, VEGF receptor 1, VEGF inhibition, tumor angiogenesis, anticancer activity, pharmacokinetics, tumor vascularization, humanized monoclonal antibody, protein engineering
- MeSH terms
- Animals, Antineoplastic Agents, Bone Neoplasms, Cell Division, Endothelium, Vascular, Extracellular Matrix, Humans, Immunoglobulin G, Immunoglobulin Constant Regions, Lymphokines, Melanoma, Experimental, Mice, Inbred BALB C, Phosphorylation, Proto-Oncogene Proteins, Rhabdomyosarcoma, Umbilical Veins, Drug Design, Protein Engineering, Endothelial Growth Factors, 3T3 Cells, Receptor Protein-Tyrosine Kinases, Vascular Endothelial Growth Factor Receptor-1, Vascular Endothelial Growth Factors, Vascular Endothelial Growth Factor A, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: VEGF-Trap: A VEGF blocker with potent antitumor effects. https://app.cochat.ai/papers/10.1073/pnas.172398299
- The paper
- Holash, J., Davis, S., Papadopoulos, N., Croll, S. D., Ho, L., Russell, M., Boland, P., Leidich, R., Hylton, D., Burova, E., Ioffe, E., Huang, T., Radziejewski, C., Bailey, K., Fandl, J. P., Daly, T., Wiegand, S. J., Yancopoulos, G. D., & Rudge, J. S. (2002). VEGF-Trap: A VEGF blocker with potent antitumor effects. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.172398299
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.